This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

    More

    Page   1/6   
  • 2014 Global life sciences sector outlook
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • The quest for value in health care: A place for consumers
    Three key disrupters are driving an increasingly consumer-centric health care system. How are consumers responding? What are the implications for the industry? And what steps can health care providers, health plans and life sciences companies consider to help win in this new marketplace?
  • Update: Privacy and security of protected health information
    The permanent HIPAA audit program commences in 2014, and the importance of ongoing risk analysis is a central feature of these audits. Industry stakeholders should consider evaluating their HIPAA privacy and security controls as soon as possible.
  • Invigorating biopharma: How the three rules can drive superior performance
    Though changing industry dynamics may call for a focus on cost containment in the short term, biopharma companies can emerge with new strategies that are again oriented toward non-price value and growth.
  • Health care reform: Redefining biopharma innovation
    Health care reform encompasses legislation that has been signed in the recent past related to the access and delivery of healthcare, notably the Affordable Care Act (ACA) passed in 2010, as well as broader, nonreversible trends in the market. Reform culminates into a heightened focus on reducing cost while increasing the quality of care, which will likely force a new definition of innovation to emerge for biopharma.
  • Operating under consent decree
    Managing a Life Sciences company through a major regulatory action.
  • The three rules in medical technology: The transformation of an industry
    Viewing performance through the lens of three straightforward rules can help medical technology companies navigate profound changes in the U.S. health care ecosystem.
  • 2014 U.S. Life Sciences Outlook: Challenges, trends and strategies that may shape your business
    Deloitte LLP’s Terry Hisey, vice chairman and U.S. Life Sciences sector leader, discusses what 2014 could bring for life sciences companies?
  • Measuring the return from Pharmaceutical innovation 2013
    This Deloitte report is the fourth in an annual series exploring the pharmaceutical industry’s performance in generating a return from its investment in new product innovation.
  • Health care costs, benefits and reform: What’s the next move for employers?
    Deloitte’s 2013 survey of U.S. employers reveals concern and uncertainty about health care system performance, Affordable Care Act (ACA) preparedness, cost-reduction strategies and the quest to find value.
  • Page   1/6